source
- FDA rejects Summit Therapeutics' lung cancer drug ivonescimab, citing insufficient survival benefitThe U.S. Food and Drug Administration issued a complete response letter rejecting the lung‑cancer therapy ivonescimab, which is being developed by Summit Therapeutics in partnership with Akeso. In…
- FDA clears Roche's Wilserdly pill for certain ER-positive, HER2-negative breast cancersThe U.S. Food and Drug Administration has approved Roche's new oral therapy Wilserdly for a specific group of breast cancer patients. The drug is indicated for adults with estrogen receptor‑positi…